Skip to main content
OpenTrials

Clinical trial condition

Neurogenic Detrusor Overactivity

Explore clinical trials studying Neurogenic Detrusor Overactivity. Study availability and eligibility vary by location and protocol.

19 public trials 3 recruiting studies
Refine in advanced search Browse all conditions

Neurogenic Detrusor Overactivity trial results

Recruiting

Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC

NCT05491525

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Central Nervous System Diseases, +30 more
Locations
  • Arkansas Childrens Hospital Little Rock, Arkansas, United States
  • Children's Hospital of Orange County Orange, California, United States
  • Children's Hospital Colorado Aurora, Colorado, United States
  • Nemours Childrens Health, Jacksonville Jacksonville, Florida, United States
View all 38 locations
View Trial Details
Recruiting

Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adults With Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization

NCT06596291

Conditions
Central Nervous System Diseases, Nervous System Diseases, Neurogenic Detrusor Overactivity, +4 more
Locations
  • Rancho Los Amigos National Rehabilitation Center Downey, California, United States
  • University of Michigan Rogel Cancer Center Ann Arbor, Michigan, United States
  • Sidney Kimmel Medical College Philadelphia, Pennsylvania, United States
  • UTHealth Houston / TIRR Memorial Hermann Houston, Texas, United States
View Trial Details
Completed

A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity

NCT01565694

Conditions
Neurogenic Detrusor Overactivity
Locations
  • Site US1008 Tarrytown, New York, United States
  • Site US1010 Cincinnati, Ohio, United States
  • Site BE3201 Ghent, Belgium
  • Site BR5505 São José do Rio Preto, São Paulo, Brazil
View all 21 locations
View Trial Details
Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)

NCT02526979

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Lower Urinary Tract Symptoms, +10 more
Locations
  • Site DK45002 Aalborg, Denmark
  • Site DK45001 Aarhus, Denmark
  • Site PL48001 Warsaw, Poland
View Trial Details
Completed

A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)

NCT01981954

Conditions
Neurogenic Detrusor Overactivity, Pediatric
Locations
  • Site US1008 Pediatric Urology Associates, P.C. Tarrytown, New York, United States
  • Site BE3203 Gent University Hospital Ghent, Belgium
  • Site PH6301 Philippines Children's Medical Center Manila, Philippines
  • Site PL4803 Uniwersyteckie Centrum Kliniczne Gdansk, Poland
View Trial Details
Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder

NCT02211846

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Lower Urinary Tract Symptoms, +11 more
Locations
  • Site BE32009 Univ.Ziekenhuis Antwerpen Edegem, Belgium
  • Site BE32003 Gent University Hospital Ghent, Belgium
  • Site BE32004 AZ Groeninge, Campus Vercruyss Kortrijk, Belgium
  • Site BE32011 U.Z. Leuven Leuven, Belgium
View all 13 locations
View Trial Details

Related conditions